Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice
Authors
Keywords
Cannabinoids, VCE-003.2, CBGA-Q, CBGA-Q-Salt, PPAR-γ receptors, Mitochondrial dysfunction, 6-Hydroxydopamine, Parkinson's disease
Journal
MOLECULAR AND CELLULAR NEUROSCIENCE
Volume 110, Issue -, Pages 103583
Publisher
Elsevier BV
Online
2020-12-17
DOI
10.1016/j.mcn.2020.103583
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Perspectives on Cannabis-Based Therapy of Multiple Sclerosis: A Mini-Review
- (2020) Miriam Mecha et al. Frontiers in Cellular Neuroscience
- Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration
- (2019) José Aguareles et al. Translational Neurodegeneration
- Cannabinoid receptor as a potential therapeutic target for Parkinson’s Disease
- (2019) Himadri Shekhaar Baul et al. BRAIN RESEARCH BULLETIN
- 7,8,4’-Trihydroxyisoflavone, a Metabolized Product of Daidzein, Attenuates 6-Hydroxydopamine-Induced Neurotoxicity in SH-SY5Y Cells
- (2019) Yong-Hyun Ko et al. Biomolecules & Therapeutics
- Endocannabinoid System in Spinocerebellar Ataxia Type-3 and Other Autosomal-Dominant Cerebellar Ataxias: Potential Role in Pathogenesis and Expected Relevance as Neuroprotective Targets
- (2019) María Gómez-Ruiz et al. Frontiers in Molecular Neuroscience
- Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson’s Disease
- (2019) Sonia Burgaz et al. MOLECULES
- Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson’s Disease and l-DOPA-Induced Dyskinesia
- (2019) Nilson Carlos Ferreira Junior et al. NEUROTOXICITY RESEARCH
- Endocannabinoid system and adult neurogenesis: a focused review
- (2019) Sergio Oddi et al. CURRENT OPINION IN PHARMACOLOGY
- Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation
- (2018) Janos Paloczi et al. ANTIOXIDANTS & REDOX SIGNALING
- β-Caryophyllene (BCP) ameliorates MPP+ induced cytotoxicity
- (2018) Guifang Wang et al. BIOMEDICINE & PHARMACOTHERAPY
- The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes
- (2018) Javier Fernández-Ruiz BRITISH JOURNAL OF PHARMACOLOGY
- In Vitro Model of Neuroinflammation: Efficacy of Cannabigerol, a Non-Psychoactive Cannabinoid
- (2018) Agnese Gugliandolo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor
- (2018) Concepción García et al. Journal of Neuroinflammation
- Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system
- (2018) Maria S. Aymerich et al. BIOCHEMICAL PHARMACOLOGY
- GPR55: A therapeutic target for Parkinson's disease?
- (2017) Marta Celorrio et al. NEUROPHARMACOLOGY
- Can cannabinoids be a potential therapeutic tool in amyotrophic lateral sclerosis?
- (2016) Emanuela Mazzon et al. Neural Regeneration Research
- THC (Δ9-Tetrahydrocannabinol) Exerts Neuroprotective Effect in Glutamate-affected Murine Primary Mesencephalic Cultures Through Restoring Mitochondrial Membrane Potential and Anti-apoptosis Involving CB1Receptor-dependent Mechanism
- (2016) Chi Huu Nguyen et al. PHYTOTHERAPY RESEARCH
- Cannabinoids to treat spinal cord injury
- (2016) Angel Arevalo-Martin et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson's disease
- (2016) Yolanda Gómez-Gálvez et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Cannabinoid-induced autophagy: Protective or death role?
- (2016) Lia Costa et al. PROSTAGLANDINS & OTHER LIPID MEDIATORS
- VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington’s disease
- (2016) Javier Díaz-Alonso et al. Scientific Reports
- Cannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson's Disease
- (2016) Hayate Javed et al. Frontiers in Neuroscience
- Neuroprotective Effect of JZL184 in MPP+-Treated SH-SY5Y Cells Through CB2 Receptors
- (2015) María S. Aymerich et al. MOLECULAR NEUROBIOLOGY
- Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications
- (2015) Javier Fernández-Ruiz et al. Neurotherapeutics
- Endocannabinoid signalling in Alzheimer's disease
- (2015) Nazia Maroof et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- A Cannabigerol Derivative Suppresses Immune Responses and Protects Mice from Experimental Autoimmune Encephalomyelitis
- (2014) Francisco J. Carrillo-Salinas et al. PLoS One
- An alternate binding site for PPARγ ligands
- (2014) Travis S. Hughes et al. Nature Communications
- A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis
- (2012) Aitor G. Granja et al. Journal of Neuroimmune Pharmacology
- Δ9-tetrahydrocannabinol (Δ9-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease
- (2012) C. B. Carroll et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ9-THCV in animal models of Parkinson's disease
- (2011) C García et al. BRITISH JOURNAL OF PHARMACOLOGY
- Endocannabinoids and traumatic brain injury
- (2011) Esther Shohami et al. BRITISH JOURNAL OF PHARMACOLOGY
- Cannabinoid Receptor Type 1 Protects Nigrostriatal Dopaminergic Neurons against MPTP Neurotoxicity by Inhibiting Microglial Activation
- (2011) Y. C. Chung et al. JOURNAL OF IMMUNOLOGY
- Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for Parkinson disease studies
- (2010) Fernanda Martins Lopes et al. BRAIN RESEARCH
- The CB1 antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease
- (2009) J.E. Kelsey et al. BEHAVIOURAL BRAIN RESEARCH
- Cannabidiol: A Promising Drug for Neurodegenerative Disorders?
- (2009) Teresa Iuvone et al. CNS Neuroscience & Therapeutics
- WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease
- (2009) David A. Price et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors
- (2009) Sandra Pérez-Rial et al. NEUROBIOLOGY OF AGING
- The cannabinoid CP55,940 prolongs survival and improves locomotor activity in Drosophila melanogaster against paraquat: Implications in Parkinson's disease
- (2008) M. Jimenez-Del-Rio et al. NEUROSCIENCE RESEARCH
- Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and α-synuclein-deleted mice
- (2007) Daniel Alvarez-Fischer et al. EXPERIMENTAL NEUROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started